Colorectal Cancer
Conditions
Keywords
dendritic cell, IL-12, IL-18, cytotoxicity
Brief summary
The purpose of this work: to assess the tolerability and effectiveness of the autogemotherapy method on the basis of autologous antigen-activated dendritic cells in the treatment of patients with colorectal cancer. This technology is intended for complex treatment of patients with colorectal cancer and is aimed at preventing the occurrence and treatment of secondary foci. The need for this technology is justified by the widespread occurrence of colorectal cancer, a decrease in the average age at onset of the disease, and the chemoresistantness of locally advanced forms of cancer.
Detailed description
Currently, technologies are being developed to improve the clinical outcomes of patients with complex treatment of colorectal cancer. Many patients are immunosuppressed after surgical, radiation and chemotherapeutic treatment, which leads to dysfunction of T cells, resulting in tumor cells avoiding immune surveillance. Restoration of antitumor immunity during immunotherapy is one of the modern approaches in the treatment of colorectal cancer, which contributes to the formation of an effective specific immune response, the destruction of tumor cells while minimizing toxicity. Dendritic cells (DC) and the lymphocytes induced by them are one of the most effective methods for the destruction of residual cancer cells, which are the leading cause of relapse and metastasis.
Interventions
BIOLOGICALImmunotherapy based on dendritic cells
Intravenous injection of cells
Sponsors
Research Institute of Fundamental and Clinical Immunology
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Patients with colorectal cancer receive a cellular preparation consisting of dendritic cells loaded with tumor lysate antigens and activated mononuclear cells.
Eligibility
Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. For the first time established morphologically confirmed diagnosis of colorectal cancer 2. Patients with II A, II B, II C, III A, III B, III C stages of colorectal cancer; 3. Patients with progressive or primary IV stage of colorectal cancer with cytologically confirmed and accessible soft tissue metastases; 4. Absence of severe somatic pathology in which medical intervention (at the stage of obtaining biological material or the stage of immunotherapy) will only worsen the patient's condition, 5. The patient's desire.
Exclusion criteria
1. Pregnancy at any time, 2. Impossibility of correction of therapy of concomitant diseases, if the taken preparations are proved to influence the immune status, 3. Rapid progression of the underlying disease, in which the use of immunotherapy is deontologically unjustified, 4. Individual intolerance to the components of the vaccine and / or the development of severe side effects on any of the components, 5. Refusal of the patient to participate in the study in oral or written form. 6. Patient involvement in any other clinical study (including those that the patient has not been informed by the direct oncologist who has been treated, but which has become known already after the beginning of any stage of the study).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Сytotoxicity | 6 months | A study of the cytotoxic activity of peripheral blood mononuclear cells against tumor cells of the COLO 320 HSR line. The result will be presented as the level of cytotoxicity (%) against the cells of the tumor line. The determination of cytotoxicity is carried out using a lactate dehydrogenase test (Promega). The level of the enzyme is proportional to the level of cytotoxicity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Parameters of peripheral blood | 6 months | Leukocyte formula, the enzyme content (lactate dehydrogenase, alkaline phosphatase, liver enzymes) of C-reactive protein, creatinine |
| Immune status indicators | 6 months | We investigate the content of CD 3+, CD 4+, CD 8+, CD 19+, CD 16+/56+ cells, HLA-DR on CD 14 monocytes |
| The content of immunosuppressive populations | 6 months | We investigate the content of T-regulatory cells, myeloid suppressors, myeloid and plasmacytoid dendritic cells |
| Interrogation of the patient using a visual analogue scale | 6 months | The patient evaluates his state in points. The patient is assessed such symptoms as fatigue, irritability, anorexia, nausea, pain, sleep disturbance. |
| Relapse-free period | 36 months | A study of the period between the onset of complex treatment and immunotherapy until the recurrence of the disease. |
Countries
Russia
Contacts
Primary ContactEkaterina V. Kulikova, PhD
Outcome results
None listed